Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice.
A technically easy, noninvasive means of delivering molecules to alveoli, which act selectively or specifically in the lung, would be experimentally and therapeutically useful. As proof of principle, we took advantage of the spreading ability of pulmonary surface active material (InfaSurf), mixed it with elastase, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) small inhibitory RNA (siRNA), or all-trans retinoic acid (ATRA), and instilled microliter amounts of the mixture into the nose of lightly anesthetized mice. One instillation of elastase caused diffuse alveolar destruction (emphysema) demonstrating widespread alveolar delivery. A single nasal instillation of GAPDH siRNA, compared with scrambled GAPDH siRNA, lowered GAPDH protein in lung, heart, and kidney by approximately 50-70% 1 and 7 days later. To test the possibility of lung-specific delivery of a potentially therapeutic drug, we administered ATRA and monitored its effect on expression of cellular retinol binding protein (CRBP)-1 mRNA, whose translation product is a key molecule in retinoid metabolism. Given intranasally, ATRA elevated CRBP-1 mRNA 4.3-fold in a lung-specific manner. The same dose and dose schedule of ATRA given intraperitoneally increased CRBP-1 mRNA only approximately 1.8-fold in lung; intraperitoneally administered ATRA elevated expression of CRBP-1 mRNA 1.7-fold or more in brain cortex, cerebellum, and testes, thereby increasing the risk of untoward effects. This simple noninvasive technique allows regulation of specific proteins in the lung and lung-specific delivery of reagents of experimental and potentially therapeutic importance.
Massaro
Donald
D
Lung Biology Laboratory, Department of Medicine, Georgetown University School of Medicine, Washington, District of Columbia 20057-1481, USA. massarod@georgetown.edu
Massaro
Gloria Decarlo
GD
Clerch
Linda Biadasz
LB
D000281:Administration, Intranasal; D000818:Animals; D004646:Emphysema / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000235:genetics; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011650:Pulmonary Alveoli / Q000378:metabolism*; D034741:RNA, Small Interfering / Q000493:pharmacokinetics*; D013501:Surface-Active Agents / Q000494:pharmacology
D034741:RNA, Small Interfering; D013501:Surface-Active Agents; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases